Navigation Links
EAU position statement on screening for prostate cancer
Date:4/16/2009

Arnhem, April 2009 -- The European Association of Urology (EAU) has taken into consideration the recent scientific information on randomised screening studies on prostate cancer (Schrder et al, NEJM 2009). Based on the results of the European Randomised Study for Screening of Prostate Cancer (ERSPC), the EAU has formulated a position statement regarding prostate cancer screening in Europe, and the subsequent actions to be taken by health professionals and health authorities.

In summary, the ERSPC reports on a relative prostate cancer mortality reduction of at least 20% by PSA-based population screening in 162,000 asymptomatic men aged 55-69 years. For every prostate cancer death prevented, 1,410 men have to undergo screening, while 48 are needed to be treated in excess of the control group population to save one prostate cancer death. Results of the PLCO (Prostate, Lung, Colon and Ovary) US randomised study of screening were also published in the same issue of the NEJM (Andriole et al, NEJM 2009) and to date show no significant effect of screening on mortality from the disease, but suffered from a significant level of contamination in the control arm. The study continues.

The EAU adopts the conclusions of the ERSPC study and recognizes the benefit of screening in terms of mortality reduction, as well as the adverse effects of overdiagnosis and overtreatment of prostate cancers which could be quantified for the first time in the setting of a randomized screening study. Further publication of relevant data is awaited from the ERSPC group in due course to inform the debate.

In the interest of men's health in Europe and elsewhere, the EAU formulates the following statements:

  • Prostate cancer is a major health problem, and one of the main causes of male cancer deaths. However, current published data are insufficient to recommend the adoption of population screening for prostate cancer as a public health policy due to the large overtreatment effect. Before screening is considered by national health authorities, the level of current opportunistic screening, overdiagnosis, overtreatment, quality of life, costs, and cost-effectiveness should be taken into account.

  • Overdiagnosis of prostate cancer leads potentially to significant overtreatment. Health professionals, especially urologists, should avoid overtreatment by developing safe methods of cancer surveillance/monitoring without invasive therapy. Invasive therapies should be tailored to patients' needs and the prognosis of cancers diagnosed.

  • Current screening algorithms are insufficient due to a lack of specificity and lack of selectivity for aggressive cancers which require treatment. The development of novel diagnostic and prognostic markers and imaging modalities is needed urgently to enhance the predictive value of screening tools.

  • In the absence of population screening, the EAU advises men who consider screening by PSA testing and prostate biopsy to obtain information on the risks and benefits of screening and individual risk assessment.

  • The EAU and the ERSPC study group represent essential European stakeholders to further develop health strategies for prostate cancer screening.

  • The EAU promotes the quality of care for prostate cancer patients in Europe in collaboration with the patient support organization Europa Uomo (www.europa-uomo.org) through the development of information support and guidelines.

  • The EAU wishes to support and foster research needed to develop reliable active surveillance protocols for low-risk prostate cancers, prognostic markers, and targeted therapies in order to deliver optimal patient care.


'/>"/>

Contact: Lindy Brouwer
l.brouwer@uroweb.org
0031-263-890-680
European Association of Urology
Source:Eurekalert

Related medicine news :

1. Patient Movement Forms in Opposition to FDA Position that the Patient's Own Stem Cells are Drugs
2. Shamir Optical Industry Ltd. Announces Receipt of Notice from Nasdaq of Noncompliance with Nasdaq Audit Committee Composition Requirements
3. Harris Corporation Donates $10,000 to Wounded Warrior Project during HIMSS09 Healthcare IT Conference and Exposition
4. Babys Sleep Position May Not Affect Severity of Head Flattening
5. Physician Group Opposes FDA's Position on Adult Stem Cells
6. Discovery may result in new test to determine predisposition to cancer
7. Kenya Government Appoints Emergency Health Workers to Permanent Positions
8. Researchers Report Combined Molecules in Red Wine by Far Exceed the Biological Activity of Plain Resveratrol, Consistent With the Composition of Longevinex(R)
9. Insmed Announces FDA Issues Statement Regarding Position on Allowing Patients With ALS Access to IPLEX(TM) Under an IND
10. Operation Rescue Launches Opposition to Gov. Sebelius Confirmation as HHS Secretary
11. Cogdell Spencer Names Herritz and Wolters to Key Leadership Positions Within Erdman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
(Date:6/23/2016)... June 23, 2016 Research and ... Procedure Volumes: Global Analysis (United States, China, Japan, Brazil, ... report to their offering. ... for healthcare business planners, provides surgical procedure volume data ... trends with an in-depth analysis of growth drivers and ...
Breaking Medicine Technology: